

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**COMP/M.7058 - EQT VI / TERVEYSTALO HEALTHCARE**

**SECTION 1.2**

**Description of the concentration**

1. On 28 October 2013, the European Commission received a notification of the proposed concentration pursuant to Article 4 of Council Regulation (EC) No. 139/2004<sup>1</sup> by which the undertaking EQT VI Limited (“EQT VI”, Guernsey, the UK), part of the EQT group of private equity funds (“EQT”, Guernsey, the UK), acquires within the meaning of Article 3.1(b) of the Merger Regulation sole control of Terveystalo Healthcare Holding Oy (“Terveystalo”) by way of purchase of shares.
2. EQT VI is an investment fund, which is part of EQT. EQT has portfolio companies active in various industries. These include medical device companies BSN Medical (wound care, compression therapy and orthopaedics products), Atos Medical (ear, nose and throat products) and HTL-Stefa (safety lancets, personal lancets and pen needles).
3. Terveystalo is a Finnish healthcare service company. Terveystalo’s customers include private individuals, companies and organizations, insurance companies and the public sector.

---

<sup>1</sup> OJ L 24, 29.1.2004, p. 1 (the “Merger Regulation”).